Rapid development of pulmonary Mycobacterium avium infection during chemoradiotherapy followed by durvalumab treatment in a locally advanced NSCLC patient

Lung Cancer. 2021 Mar:153:182-183. doi: 10.1016/j.lungcan.2021.01.021. Epub 2021 Jan 30.

Authors

Keisuke Baba¹, Tatsuya Yoshida², Mika Shiotsuka³, Osamu Kobayashi³, Satoshi Iwata³, Yuichiro Ohe¹

Affiliations

¹ Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
² Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. Electronic address: [email protected].
³ Department of Infectious Diseases, National Cancer Center Hospital, Tokyo, Japan.

PMID: 33546908
DOI: 10.1016/j.lungcan.2021.01.021

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal / therapeutic use
Chemoradiotherapy
Humans
Lung Neoplasms* / drug therapy
Mycobacterium avium

Substances

Antibodies, Monoclonal
durvalumab